nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmethylphenidate—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—ALDH2—esophageal cancer	0.0108	0.0582	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Alpha-synuclein signaling—UCHL1—esophageal cancer	0.00639	0.0343	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Alpha-synuclein signaling—FKBP1A—esophageal cancer	0.00608	0.0326	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00597	0.032	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Parkinsons Disease Pathway—UCHL1—esophageal cancer	0.00543	0.0291	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00472	0.0253	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00414	0.0222	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Dopaminergic Neurogenesis—SOX2—esophageal cancer	0.00412	0.0221	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—CYP2E1 reactions—CYP2A6—esophageal cancer	0.0037	0.0199	CbGpPWpGaD
Dexmethylphenidate—SLC6A4—NRF2 pathway—ALDH3A1—esophageal cancer	0.0035	0.0188	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00317	0.017	CbGpPWpGaD
Dexmethylphenidate—SLC6A4—NRF2 pathway—BLVRB—esophageal cancer	0.00312	0.0167	CbGpPWpGaD
Dexmethylphenidate—SLC6A2—NRF2 pathway—ALDH3A1—esophageal cancer	0.00301	0.0162	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00292	0.0156	CbGpPWpGaD
Dexmethylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.00282	0.0151	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00274	0.0147	CbGpPWpGaD
Dexmethylphenidate—SLC6A2—NRF2 pathway—BLVRB—esophageal cancer	0.00268	0.0144	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—NRF2 pathway—ALDH3A1—esophageal cancer	0.00267	0.0143	CbGpPWpGaD
Dexmethylphenidate—SLC6A4—NRF2 pathway—PRDX1—esophageal cancer	0.00265	0.0142	CbGpPWpGaD
Dexmethylphenidate—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.00258	0.0138	CbGpPWpGaD
Dexmethylphenidate—SLC6A4—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.00252	0.0135	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.0025	0.0134	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—NRF2 pathway—BLVRB—esophageal cancer	0.00238	0.0128	CbGpPWpGaD
Dexmethylphenidate—SLC6A4—NRF2 pathway—SLC39A6—esophageal cancer	0.00237	0.0127	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Xenobiotics—CYP2A6—esophageal cancer	0.00229	0.0123	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.00229	0.0123	CbGpPWpGaD
Dexmethylphenidate—SLC6A2—NRF2 pathway—PRDX1—esophageal cancer	0.00228	0.0122	CbGpPWpGaD
Dexmethylphenidate—SLC6A4—NRF2 pathway—ADH7—esophageal cancer	0.00226	0.0121	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00221	0.0118	CbGpPWpGaD
Dexmethylphenidate—SLC6A4—Circadian rythm related genes—CRTC1—esophageal cancer	0.00205	0.011	CbGpPWpGaD
Dexmethylphenidate—SLC6A2—NRF2 pathway—SLC39A6—esophageal cancer	0.00203	0.0109	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—NRF2 pathway—PRDX1—esophageal cancer	0.00202	0.0108	CbGpPWpGaD
Dexmethylphenidate—Ecchymosis—Methotrexate—esophageal cancer	0.00195	0.00239	CcSEcCtD
Dexmethylphenidate—Neoplasm—Methotrexate—esophageal cancer	0.00195	0.00239	CcSEcCtD
Dexmethylphenidate—Urinary tract disorder—Cisplatin—esophageal cancer	0.00194	0.00239	CcSEcCtD
Dexmethylphenidate—SLC6A2—NRF2 pathway—ADH7—esophageal cancer	0.00194	0.0104	CbGpPWpGaD
Dexmethylphenidate—Liver function test abnormal—Capecitabine—esophageal cancer	0.00194	0.00238	CcSEcCtD
Dexmethylphenidate—Connective tissue disorder—Cisplatin—esophageal cancer	0.00194	0.00238	CcSEcCtD
Dexmethylphenidate—Urethral disorder—Cisplatin—esophageal cancer	0.00193	0.00237	CcSEcCtD
Dexmethylphenidate—Gynaecomastia—Methotrexate—esophageal cancer	0.00193	0.00237	CcSEcCtD
Dexmethylphenidate—Abdominal pain upper—Capecitabine—esophageal cancer	0.00192	0.00236	CcSEcCtD
Dexmethylphenidate—Visual impairment—Cisplatin—esophageal cancer	0.0019	0.00233	CcSEcCtD
Dexmethylphenidate—Breast disorder—Capecitabine—esophageal cancer	0.0019	0.00233	CcSEcCtD
Dexmethylphenidate—Nasopharyngitis—Capecitabine—esophageal cancer	0.00188	0.00231	CcSEcCtD
Dexmethylphenidate—Gastritis—Capecitabine—esophageal cancer	0.00186	0.00228	CcSEcCtD
Dexmethylphenidate—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00185	0.00227	CcSEcCtD
Dexmethylphenidate—Eye disorder—Cisplatin—esophageal cancer	0.00184	0.00226	CcSEcCtD
Dexmethylphenidate—Lymphadenopathy—Methotrexate—esophageal cancer	0.00183	0.00225	CcSEcCtD
Dexmethylphenidate—Cardiac disorder—Cisplatin—esophageal cancer	0.00183	0.00225	CcSEcCtD
Dexmethylphenidate—Flushing—Cisplatin—esophageal cancer	0.00183	0.00225	CcSEcCtD
Dexmethylphenidate—Influenza—Capecitabine—esophageal cancer	0.00181	0.00223	CcSEcCtD
Dexmethylphenidate—Asthma—Capecitabine—esophageal cancer	0.00181	0.00223	CcSEcCtD
Dexmethylphenidate—SLC6A3—NRF2 pathway—SLC39A6—esophageal cancer	0.0018	0.00967	CbGpPWpGaD
Dexmethylphenidate—Diabetes mellitus—Methotrexate—esophageal cancer	0.0018	0.00221	CcSEcCtD
Dexmethylphenidate—Photosensitivity—Methotrexate—esophageal cancer	0.00178	0.00219	CcSEcCtD
Dexmethylphenidate—Immune system disorder—Cisplatin—esophageal cancer	0.00178	0.00219	CcSEcCtD
Dexmethylphenidate—CYP2D6—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00178	0.00954	CbGpPWpGaD
Dexmethylphenidate—Mediastinal disorder—Cisplatin—esophageal cancer	0.00177	0.00218	CcSEcCtD
Dexmethylphenidate—Angina pectoris—Capecitabine—esophageal cancer	0.00177	0.00217	CcSEcCtD
Dexmethylphenidate—Arrhythmia—Cisplatin—esophageal cancer	0.00176	0.00216	CcSEcCtD
Dexmethylphenidate—Bronchitis—Capecitabine—esophageal cancer	0.00174	0.00214	CcSEcCtD
Dexmethylphenidate—Alopecia—Cisplatin—esophageal cancer	0.00174	0.00214	CcSEcCtD
Dexmethylphenidate—Abdominal discomfort—Capecitabine—esophageal cancer	0.00174	0.00214	CcSEcCtD
Dexmethylphenidate—Pancytopenia—Capecitabine—esophageal cancer	0.00172	0.00212	CcSEcCtD
Dexmethylphenidate—SLC6A3—NRF2 pathway—ADH7—esophageal cancer	0.00172	0.00922	CbGpPWpGaD
Dexmethylphenidate—Malnutrition—Cisplatin—esophageal cancer	0.00171	0.00211	CcSEcCtD
Dexmethylphenidate—Erythema—Cisplatin—esophageal cancer	0.00171	0.00211	CcSEcCtD
Dexmethylphenidate—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00169	0.00207	CcSEcCtD
Dexmethylphenidate—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00166	0.00203	CcSEcCtD
Dexmethylphenidate—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00166	0.00203	CcSEcCtD
Dexmethylphenidate—Weight increased—Capecitabine—esophageal cancer	0.00165	0.00203	CcSEcCtD
Dexmethylphenidate—Visual disturbance—Methotrexate—esophageal cancer	0.00165	0.00203	CcSEcCtD
Dexmethylphenidate—Muscle spasms—Cisplatin—esophageal cancer	0.00165	0.00203	CcSEcCtD
Dexmethylphenidate—Weight decreased—Capecitabine—esophageal cancer	0.00164	0.00202	CcSEcCtD
Dexmethylphenidate—SLC6A4—NRF2 pathway—ABCC2—esophageal cancer	0.00164	0.00879	CbGpPWpGaD
Dexmethylphenidate—Pneumonia—Capecitabine—esophageal cancer	0.00163	0.002	CcSEcCtD
Dexmethylphenidate—SLC6A4—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.00162	0.0087	CbGpPWpGaD
Dexmethylphenidate—Infestation NOS—Capecitabine—esophageal cancer	0.00162	0.00199	CcSEcCtD
Dexmethylphenidate—Infestation—Capecitabine—esophageal cancer	0.00162	0.00199	CcSEcCtD
Dexmethylphenidate—Vision blurred—Cisplatin—esophageal cancer	0.00162	0.00199	CcSEcCtD
Dexmethylphenidate—Depression—Capecitabine—esophageal cancer	0.00161	0.00198	CcSEcCtD
Dexmethylphenidate—Tremor—Cisplatin—esophageal cancer	0.00161	0.00197	CcSEcCtD
Dexmethylphenidate—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.0016	0.00197	CcSEcCtD
Dexmethylphenidate—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00159	0.00196	CcSEcCtD
Dexmethylphenidate—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00159	0.00196	CcSEcCtD
Dexmethylphenidate—Lethargy—Methotrexate—esophageal cancer	0.00159	0.00196	CcSEcCtD
Dexmethylphenidate—Ill-defined disorder—Cisplatin—esophageal cancer	0.00159	0.00195	CcSEcCtD
Dexmethylphenidate—Myocardial infarction—Capecitabine—esophageal cancer	0.00158	0.00195	CcSEcCtD
Dexmethylphenidate—Anaemia—Cisplatin—esophageal cancer	0.00158	0.00195	CcSEcCtD
Dexmethylphenidate—Conjunctivitis—Capecitabine—esophageal cancer	0.00157	0.00193	CcSEcCtD
Dexmethylphenidate—Malaise—Cisplatin—esophageal cancer	0.00155	0.0019	CcSEcCtD
Dexmethylphenidate—Haematuria—Capecitabine—esophageal cancer	0.00154	0.00189	CcSEcCtD
Dexmethylphenidate—Leukopenia—Cisplatin—esophageal cancer	0.00153	0.00189	CcSEcCtD
Dexmethylphenidate—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00153	0.00188	CcSEcCtD
Dexmethylphenidate—Epistaxis—Capecitabine—esophageal cancer	0.00153	0.00187	CcSEcCtD
Dexmethylphenidate—SLC6A4—NRF2 pathway—NFE2L2—esophageal cancer	0.00152	0.00818	CbGpPWpGaD
Dexmethylphenidate—SLC6A4—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.0015	0.00803	CbGpPWpGaD
Dexmethylphenidate—Irritability—Methotrexate—esophageal cancer	0.00149	0.00183	CcSEcCtD
Dexmethylphenidate—Convulsion—Cisplatin—esophageal cancer	0.00149	0.00183	CcSEcCtD
Dexmethylphenidate—Mood swings—Methotrexate—esophageal cancer	0.00148	0.00182	CcSEcCtD
Dexmethylphenidate—Bradycardia—Capecitabine—esophageal cancer	0.00148	0.00182	CcSEcCtD
Dexmethylphenidate—Myalgia—Cisplatin—esophageal cancer	0.00146	0.00179	CcSEcCtD
Dexmethylphenidate—Haemoglobin—Capecitabine—esophageal cancer	0.00146	0.00179	CcSEcCtD
Dexmethylphenidate—Rhinitis—Capecitabine—esophageal cancer	0.00146	0.00179	CcSEcCtD
Dexmethylphenidate—Anxiety—Cisplatin—esophageal cancer	0.00145	0.00179	CcSEcCtD
Dexmethylphenidate—Haemorrhage—Capecitabine—esophageal cancer	0.00145	0.00178	CcSEcCtD
Dexmethylphenidate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00145	0.00178	CcSEcCtD
Dexmethylphenidate—SLC6A4—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.00145	0.00775	CbGpPWpGaD
Dexmethylphenidate—Liver function test abnormal—Methotrexate—esophageal cancer	0.00144	0.00177	CcSEcCtD
Dexmethylphenidate—Discomfort—Cisplatin—esophageal cancer	0.00144	0.00177	CcSEcCtD
Dexmethylphenidate—Pharyngitis—Capecitabine—esophageal cancer	0.00144	0.00177	CcSEcCtD
Dexmethylphenidate—Urinary tract disorder—Capecitabine—esophageal cancer	0.00143	0.00176	CcSEcCtD
Dexmethylphenidate—Connective tissue disorder—Capecitabine—esophageal cancer	0.00143	0.00175	CcSEcCtD
Dexmethylphenidate—Urethral disorder—Capecitabine—esophageal cancer	0.00142	0.00175	CcSEcCtD
Dexmethylphenidate—Breast disorder—Methotrexate—esophageal cancer	0.00141	0.00173	CcSEcCtD
Dexmethylphenidate—SLC6A2—NRF2 pathway—ABCC2—esophageal cancer	0.00141	0.00756	CbGpPWpGaD
Dexmethylphenidate—Anaphylactic shock—Cisplatin—esophageal cancer	0.0014	0.00172	CcSEcCtD
Dexmethylphenidate—Oedema—Cisplatin—esophageal cancer	0.0014	0.00172	CcSEcCtD
Dexmethylphenidate—Visual impairment—Capecitabine—esophageal cancer	0.0014	0.00172	CcSEcCtD
Dexmethylphenidate—Infection—Cisplatin—esophageal cancer	0.00139	0.00171	CcSEcCtD
Dexmethylphenidate—CYP2D6—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.00137	0.00737	CbGpPWpGaD
Dexmethylphenidate—Erythema multiforme—Capecitabine—esophageal cancer	0.00137	0.00169	CcSEcCtD
Dexmethylphenidate—Nervous system disorder—Cisplatin—esophageal cancer	0.00137	0.00169	CcSEcCtD
Dexmethylphenidate—Thrombocytopenia—Cisplatin—esophageal cancer	0.00137	0.00168	CcSEcCtD
Dexmethylphenidate—Tachycardia—Cisplatin—esophageal cancer	0.00137	0.00168	CcSEcCtD
Dexmethylphenidate—Skin disorder—Cisplatin—esophageal cancer	0.00136	0.00167	CcSEcCtD
Dexmethylphenidate—Eye disorder—Capecitabine—esophageal cancer	0.00136	0.00167	CcSEcCtD
Dexmethylphenidate—Hyperhidrosis—Cisplatin—esophageal cancer	0.00135	0.00166	CcSEcCtD
Dexmethylphenidate—Asthma—Methotrexate—esophageal cancer	0.00135	0.00166	CcSEcCtD
Dexmethylphenidate—Cardiac disorder—Capecitabine—esophageal cancer	0.00135	0.00166	CcSEcCtD
Dexmethylphenidate—Flushing—Capecitabine—esophageal cancer	0.00135	0.00166	CcSEcCtD
Dexmethylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00134	0.00717	CbGpPWpGaD
Dexmethylphenidate—Anorexia—Cisplatin—esophageal cancer	0.00133	0.00164	CcSEcCtD
Dexmethylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00133	0.00713	CbGpPWpGaD
Dexmethylphenidate—Pancreatitis—Methotrexate—esophageal cancer	0.00132	0.00163	CcSEcCtD
Dexmethylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00132	0.00708	CbGpPWpGaD
Dexmethylphenidate—Angiopathy—Capecitabine—esophageal cancer	0.00132	0.00162	CcSEcCtD
Dexmethylphenidate—Immune system disorder—Capecitabine—esophageal cancer	0.00131	0.00161	CcSEcCtD
Dexmethylphenidate—SLC6A2—NRF2 pathway—NFE2L2—esophageal cancer	0.00131	0.00703	CbGpPWpGaD
Dexmethylphenidate—SLC6A4—NRF2 pathway—CYP2A6—esophageal cancer	0.00131	0.00703	CbGpPWpGaD
Dexmethylphenidate—Mediastinal disorder—Capecitabine—esophageal cancer	0.00131	0.00161	CcSEcCtD
Dexmethylphenidate—Chills—Capecitabine—esophageal cancer	0.0013	0.0016	CcSEcCtD
Dexmethylphenidate—Arrhythmia—Capecitabine—esophageal cancer	0.0013	0.00159	CcSEcCtD
Dexmethylphenidate—Abdominal discomfort—Methotrexate—esophageal cancer	0.00129	0.00159	CcSEcCtD
Dexmethylphenidate—Alopecia—Capecitabine—esophageal cancer	0.00128	0.00158	CcSEcCtD
Dexmethylphenidate—Pancytopenia—Methotrexate—esophageal cancer	0.00128	0.00158	CcSEcCtD
Dexmethylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00128	0.00688	CbGpPWpGaD
Dexmethylphenidate—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00127	0.00157	CcSEcCtD
Dexmethylphenidate—Mental disorder—Capecitabine—esophageal cancer	0.00127	0.00156	CcSEcCtD
Dexmethylphenidate—Malnutrition—Capecitabine—esophageal cancer	0.00126	0.00155	CcSEcCtD
Dexmethylphenidate—Erythema—Capecitabine—esophageal cancer	0.00126	0.00155	CcSEcCtD
Dexmethylphenidate—Paraesthesia—Cisplatin—esophageal cancer	0.00126	0.00154	CcSEcCtD
Dexmethylphenidate—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00125	0.00154	CcSEcCtD
Dexmethylphenidate—SLC6A3—NRF2 pathway—ABCC2—esophageal cancer	0.00125	0.0067	CbGpPWpGaD
Dexmethylphenidate—Dyspnoea—Cisplatin—esophageal cancer	0.00125	0.00153	CcSEcCtD
Dexmethylphenidate—Erectile dysfunction—Methotrexate—esophageal cancer	0.00124	0.00153	CcSEcCtD
Dexmethylphenidate—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00123	0.00151	CcSEcCtD
Dexmethylphenidate—Back pain—Capecitabine—esophageal cancer	0.00122	0.0015	CcSEcCtD
Dexmethylphenidate—Decreased appetite—Cisplatin—esophageal cancer	0.00122	0.00149	CcSEcCtD
Dexmethylphenidate—Muscle spasms—Capecitabine—esophageal cancer	0.00121	0.00149	CcSEcCtD
Dexmethylphenidate—Pneumonia—Methotrexate—esophageal cancer	0.00121	0.00149	CcSEcCtD
Dexmethylphenidate—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00121	0.00148	CcSEcCtD
Dexmethylphenidate—Infestation NOS—Methotrexate—esophageal cancer	0.0012	0.00148	CcSEcCtD
Dexmethylphenidate—Drowsiness—Methotrexate—esophageal cancer	0.0012	0.00148	CcSEcCtD
Dexmethylphenidate—Infestation—Methotrexate—esophageal cancer	0.0012	0.00148	CcSEcCtD
Dexmethylphenidate—Depression—Methotrexate—esophageal cancer	0.0012	0.00148	CcSEcCtD
Dexmethylphenidate—Pain—Cisplatin—esophageal cancer	0.0012	0.00147	CcSEcCtD
Dexmethylphenidate—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00119	0.00147	CcSEcCtD
Dexmethylphenidate—Vision blurred—Capecitabine—esophageal cancer	0.00119	0.00146	CcSEcCtD
Dexmethylphenidate—Tremor—Capecitabine—esophageal cancer	0.00118	0.00146	CcSEcCtD
Dexmethylphenidate—Ill-defined disorder—Capecitabine—esophageal cancer	0.00117	0.00144	CcSEcCtD
Dexmethylphenidate—SLC6A2—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00117	0.00629	CbGpPWpGaD
Dexmethylphenidate—Conjunctivitis—Methotrexate—esophageal cancer	0.00117	0.00144	CcSEcCtD
Dexmethylphenidate—Anaemia—Capecitabine—esophageal cancer	0.00117	0.00144	CcSEcCtD
Dexmethylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00117	0.00625	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—NRF2 pathway—NFE2L2—esophageal cancer	0.00116	0.00623	CbGpPWpGaD
Dexmethylphenidate—Sweating—Methotrexate—esophageal cancer	0.00115	0.00142	CcSEcCtD
Dexmethylphenidate—Feeling abnormal—Cisplatin—esophageal cancer	0.00115	0.00142	CcSEcCtD
Dexmethylphenidate—Haematuria—Methotrexate—esophageal cancer	0.00115	0.00141	CcSEcCtD
Dexmethylphenidate—Malaise—Capecitabine—esophageal cancer	0.00114	0.0014	CcSEcCtD
Dexmethylphenidate—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00114	0.0014	CcSEcCtD
Dexmethylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00114	0.00609	CbGpPWpGaD
Dexmethylphenidate—Epistaxis—Methotrexate—esophageal cancer	0.00114	0.0014	CcSEcCtD
Dexmethylphenidate—Vertigo—Capecitabine—esophageal cancer	0.00114	0.0014	CcSEcCtD
Dexmethylphenidate—Syncope—Capecitabine—esophageal cancer	0.00113	0.00139	CcSEcCtD
Dexmethylphenidate—Leukopenia—Capecitabine—esophageal cancer	0.00113	0.00139	CcSEcCtD
Dexmethylphenidate—SLC6A2—NRF2 pathway—CYP2A6—esophageal cancer	0.00113	0.00605	CbGpPWpGaD
Dexmethylphenidate—SLC6A4—SIDS Susceptibility Pathways—SST—esophageal cancer	0.00112	0.00603	CbGpPWpGaD
Dexmethylphenidate—Palpitations—Capecitabine—esophageal cancer	0.00112	0.00137	CcSEcCtD
Dexmethylphenidate—Loss of consciousness—Capecitabine—esophageal cancer	0.00111	0.00137	CcSEcCtD
Dexmethylphenidate—Body temperature increased—Cisplatin—esophageal cancer	0.00111	0.00136	CcSEcCtD
Dexmethylphenidate—Cough—Capecitabine—esophageal cancer	0.0011	0.00136	CcSEcCtD
Dexmethylphenidate—Hypertension—Capecitabine—esophageal cancer	0.00109	0.00134	CcSEcCtD
Dexmethylphenidate—Haemoglobin—Methotrexate—esophageal cancer	0.00109	0.00133	CcSEcCtD
Dexmethylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00108	0.00581	CbGpPWpGaD
Dexmethylphenidate—Haemorrhage—Methotrexate—esophageal cancer	0.00108	0.00133	CcSEcCtD
Dexmethylphenidate—Arthralgia—Capecitabine—esophageal cancer	0.00108	0.00132	CcSEcCtD
Dexmethylphenidate—Chest pain—Capecitabine—esophageal cancer	0.00108	0.00132	CcSEcCtD
Dexmethylphenidate—Myalgia—Capecitabine—esophageal cancer	0.00108	0.00132	CcSEcCtD
Dexmethylphenidate—Pharyngitis—Methotrexate—esophageal cancer	0.00107	0.00132	CcSEcCtD
Dexmethylphenidate—Anxiety—Capecitabine—esophageal cancer	0.00107	0.00132	CcSEcCtD
Dexmethylphenidate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00107	0.00131	CcSEcCtD
Dexmethylphenidate—Urinary tract disorder—Methotrexate—esophageal cancer	0.00107	0.00131	CcSEcCtD
Dexmethylphenidate—Discomfort—Capecitabine—esophageal cancer	0.00106	0.00131	CcSEcCtD
Dexmethylphenidate—Urethral disorder—Methotrexate—esophageal cancer	0.00106	0.0013	CcSEcCtD
Dexmethylphenidate—Dry mouth—Capecitabine—esophageal cancer	0.00105	0.00129	CcSEcCtD
Dexmethylphenidate—Visual impairment—Methotrexate—esophageal cancer	0.00104	0.00128	CcSEcCtD
Dexmethylphenidate—Confusional state—Capecitabine—esophageal cancer	0.00104	0.00128	CcSEcCtD
Dexmethylphenidate—SLC6A3—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00104	0.00557	CbGpPWpGaD
Dexmethylphenidate—Oedema—Capecitabine—esophageal cancer	0.00103	0.00127	CcSEcCtD
Dexmethylphenidate—Hypersensitivity—Cisplatin—esophageal cancer	0.00103	0.00127	CcSEcCtD
Dexmethylphenidate—Infection—Capecitabine—esophageal cancer	0.00102	0.00126	CcSEcCtD
Dexmethylphenidate—Erythema multiforme—Methotrexate—esophageal cancer	0.00102	0.00126	CcSEcCtD
Dexmethylphenidate—Shock—Capecitabine—esophageal cancer	0.00101	0.00125	CcSEcCtD
Dexmethylphenidate—Nervous system disorder—Capecitabine—esophageal cancer	0.00101	0.00124	CcSEcCtD
Dexmethylphenidate—Eye disorder—Methotrexate—esophageal cancer	0.00101	0.00124	CcSEcCtD
Dexmethylphenidate—Thrombocytopenia—Capecitabine—esophageal cancer	0.00101	0.00124	CcSEcCtD
Dexmethylphenidate—Tachycardia—Capecitabine—esophageal cancer	0.00101	0.00124	CcSEcCtD
Dexmethylphenidate—Asthenia—Cisplatin—esophageal cancer	0.001	0.00123	CcSEcCtD
Dexmethylphenidate—Cardiac disorder—Methotrexate—esophageal cancer	0.001	0.00123	CcSEcCtD
Dexmethylphenidate—Skin disorder—Capecitabine—esophageal cancer	0.001	0.00123	CcSEcCtD
Dexmethylphenidate—SLC6A3—NRF2 pathway—CYP2A6—esophageal cancer	0.000998	0.00536	CbGpPWpGaD
Dexmethylphenidate—Hyperhidrosis—Capecitabine—esophageal cancer	0.000997	0.00123	CcSEcCtD
Dexmethylphenidate—Anorexia—Capecitabine—esophageal cancer	0.000983	0.00121	CcSEcCtD
Dexmethylphenidate—Angiopathy—Methotrexate—esophageal cancer	0.00098	0.00121	CcSEcCtD
Dexmethylphenidate—Immune system disorder—Methotrexate—esophageal cancer	0.000976	0.0012	CcSEcCtD
Dexmethylphenidate—Mediastinal disorder—Methotrexate—esophageal cancer	0.000974	0.0012	CcSEcCtD
Dexmethylphenidate—Chills—Methotrexate—esophageal cancer	0.00097	0.00119	CcSEcCtD
Dexmethylphenidate—Diarrhoea—Cisplatin—esophageal cancer	0.000957	0.00118	CcSEcCtD
Dexmethylphenidate—Alopecia—Methotrexate—esophageal cancer	0.000955	0.00117	CcSEcCtD
Dexmethylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000953	0.00511	CbGpPWpGaD
Dexmethylphenidate—Mental disorder—Methotrexate—esophageal cancer	0.000947	0.00116	CcSEcCtD
Dexmethylphenidate—Malnutrition—Methotrexate—esophageal cancer	0.000941	0.00116	CcSEcCtD
Dexmethylphenidate—Erythema—Methotrexate—esophageal cancer	0.000941	0.00116	CcSEcCtD
Dexmethylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00094	0.00504	CbGpPWpGaD
Dexmethylphenidate—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00094	0.00115	CcSEcCtD
Dexmethylphenidate—Insomnia—Capecitabine—esophageal cancer	0.000933	0.00115	CcSEcCtD
Dexmethylphenidate—Paraesthesia—Capecitabine—esophageal cancer	0.000926	0.00114	CcSEcCtD
Dexmethylphenidate—Dyspnoea—Capecitabine—esophageal cancer	0.000919	0.00113	CcSEcCtD
Dexmethylphenidate—SLC6A4—NRF2 pathway—TGFBR2—esophageal cancer	0.000919	0.00493	CbGpPWpGaD
Dexmethylphenidate—Back pain—Methotrexate—esophageal cancer	0.00091	0.00112	CcSEcCtD
Dexmethylphenidate—Dyspepsia—Capecitabine—esophageal cancer	0.000908	0.00112	CcSEcCtD
Dexmethylphenidate—SLC6A4—NRF2 pathway—HMOX1—esophageal cancer	0.000906	0.00486	CbGpPWpGaD
Dexmethylphenidate—Decreased appetite—Capecitabine—esophageal cancer	0.000896	0.0011	CcSEcCtD
Dexmethylphenidate—SLC6A4—Circadian rythm related genes—GHRL—esophageal cancer	0.000894	0.0048	CbGpPWpGaD
Dexmethylphenidate—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00089	0.00109	CcSEcCtD
Dexmethylphenidate—Vomiting—Cisplatin—esophageal cancer	0.00089	0.00109	CcSEcCtD
Dexmethylphenidate—Fatigue—Capecitabine—esophageal cancer	0.000889	0.00109	CcSEcCtD
Dexmethylphenidate—Vision blurred—Methotrexate—esophageal cancer	0.000887	0.00109	CcSEcCtD
Dexmethylphenidate—Rash—Cisplatin—esophageal cancer	0.000882	0.00108	CcSEcCtD
Dexmethylphenidate—Pain—Capecitabine—esophageal cancer	0.000882	0.00108	CcSEcCtD
Dexmethylphenidate—Constipation—Capecitabine—esophageal cancer	0.000882	0.00108	CcSEcCtD
Dexmethylphenidate—Dermatitis—Cisplatin—esophageal cancer	0.000881	0.00108	CcSEcCtD
Dexmethylphenidate—SLC6A3—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.000881	0.00473	CbGpPWpGaD
Dexmethylphenidate—Ill-defined disorder—Methotrexate—esophageal cancer	0.000873	0.00107	CcSEcCtD
Dexmethylphenidate—Anaemia—Methotrexate—esophageal cancer	0.000869	0.00107	CcSEcCtD
Dexmethylphenidate—Feeling abnormal—Capecitabine—esophageal cancer	0.00085	0.00104	CcSEcCtD
Dexmethylphenidate—Malaise—Methotrexate—esophageal cancer	0.000848	0.00104	CcSEcCtD
Dexmethylphenidate—Vertigo—Methotrexate—esophageal cancer	0.000845	0.00104	CcSEcCtD
Dexmethylphenidate—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000843	0.00104	CcSEcCtD
Dexmethylphenidate—Leukopenia—Methotrexate—esophageal cancer	0.000842	0.00103	CcSEcCtD
Dexmethylphenidate—Nausea—Cisplatin—esophageal cancer	0.000831	0.00102	CcSEcCtD
Dexmethylphenidate—SLC6A3—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.000826	0.00443	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000821	0.00441	CbGpPWpGaD
Dexmethylphenidate—Cough—Methotrexate—esophageal cancer	0.000821	0.00101	CcSEcCtD
Dexmethylphenidate—Urticaria—Capecitabine—esophageal cancer	0.000819	0.00101	CcSEcCtD
Dexmethylphenidate—Body temperature increased—Capecitabine—esophageal cancer	0.000815	0.001	CcSEcCtD
Dexmethylphenidate—Abdominal pain—Capecitabine—esophageal cancer	0.000815	0.001	CcSEcCtD
Dexmethylphenidate—Convulsion—Methotrexate—esophageal cancer	0.000815	0.001	CcSEcCtD
Dexmethylphenidate—Arthralgia—Methotrexate—esophageal cancer	0.000801	0.000984	CcSEcCtD
Dexmethylphenidate—Myalgia—Methotrexate—esophageal cancer	0.000801	0.000984	CcSEcCtD
Dexmethylphenidate—Chest pain—Methotrexate—esophageal cancer	0.000801	0.000984	CcSEcCtD
Dexmethylphenidate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000795	0.000978	CcSEcCtD
Dexmethylphenidate—Discomfort—Methotrexate—esophageal cancer	0.000791	0.000973	CcSEcCtD
Dexmethylphenidate—SLC6A2—NRF2 pathway—TGFBR2—esophageal cancer	0.00079	0.00424	CbGpPWpGaD
Dexmethylphenidate—SLC6A2—NRF2 pathway—HMOX1—esophageal cancer	0.000779	0.00418	CbGpPWpGaD
Dexmethylphenidate—Confusional state—Methotrexate—esophageal cancer	0.000774	0.000951	CcSEcCtD
Dexmethylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000772	0.00414	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000768	0.00412	CbGpPWpGaD
Dexmethylphenidate—Anaphylactic shock—Methotrexate—esophageal cancer	0.000768	0.000944	CcSEcCtD
Dexmethylphenidate—Infection—Methotrexate—esophageal cancer	0.000763	0.000937	CcSEcCtD
Dexmethylphenidate—Hypersensitivity—Capecitabine—esophageal cancer	0.00076	0.000934	CcSEcCtD
Dexmethylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000758	0.00407	CbGpPWpGaD
Dexmethylphenidate—Nervous system disorder—Methotrexate—esophageal cancer	0.000753	0.000925	CcSEcCtD
Dexmethylphenidate—Thrombocytopenia—Methotrexate—esophageal cancer	0.000752	0.000924	CcSEcCtD
Dexmethylphenidate—Skin disorder—Methotrexate—esophageal cancer	0.000746	0.000917	CcSEcCtD
Dexmethylphenidate—Hyperhidrosis—Methotrexate—esophageal cancer	0.000742	0.000912	CcSEcCtD
Dexmethylphenidate—Asthenia—Capecitabine—esophageal cancer	0.00074	0.000909	CcSEcCtD
Dexmethylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000732	0.00393	CbGpPWpGaD
Dexmethylphenidate—Anorexia—Methotrexate—esophageal cancer	0.000732	0.000899	CcSEcCtD
Dexmethylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000731	0.00392	CbGpPWpGaD
Dexmethylphenidate—Pruritus—Capecitabine—esophageal cancer	0.00073	0.000897	CcSEcCtD
Dexmethylphenidate—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000722	0.00387	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000712	0.00382	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Biological oxidations—ADH7—esophageal cancer	0.000706	0.00379	CbGpPWpGaD
Dexmethylphenidate—Diarrhoea—Capecitabine—esophageal cancer	0.000706	0.000867	CcSEcCtD
Dexmethylphenidate—SLC6A3—NRF2 pathway—TGFBR2—esophageal cancer	0.0007	0.00376	CbGpPWpGaD
Dexmethylphenidate—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000699	0.00086	CcSEcCtD
Dexmethylphenidate—Insomnia—Methotrexate—esophageal cancer	0.000694	0.000853	CcSEcCtD
Dexmethylphenidate—SLC6A3—NRF2 pathway—HMOX1—esophageal cancer	0.00069	0.0037	CbGpPWpGaD
Dexmethylphenidate—Paraesthesia—Methotrexate—esophageal cancer	0.000689	0.000847	CcSEcCtD
Dexmethylphenidate—SLC6A2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000687	0.00369	CbGpPWpGaD
Dexmethylphenidate—Dyspnoea—Methotrexate—esophageal cancer	0.000684	0.000841	CcSEcCtD
Dexmethylphenidate—Somnolence—Methotrexate—esophageal cancer	0.000682	0.000839	CcSEcCtD
Dexmethylphenidate—Dizziness—Capecitabine—esophageal cancer	0.000682	0.000838	CcSEcCtD
Dexmethylphenidate—Dyspepsia—Methotrexate—esophageal cancer	0.000676	0.000831	CcSEcCtD
Dexmethylphenidate—SLC6A4—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000675	0.00362	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Neuronal System—GNG7—esophageal cancer	0.000675	0.00362	CbGpPWpGaD
Dexmethylphenidate—Decreased appetite—Methotrexate—esophageal cancer	0.000667	0.00082	CcSEcCtD
Dexmethylphenidate—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000663	0.000815	CcSEcCtD
Dexmethylphenidate—Fatigue—Methotrexate—esophageal cancer	0.000662	0.000814	CcSEcCtD
Dexmethylphenidate—Pain—Methotrexate—esophageal cancer	0.000656	0.000807	CcSEcCtD
Dexmethylphenidate—Vomiting—Capecitabine—esophageal cancer	0.000656	0.000806	CcSEcCtD
Dexmethylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000651	0.00349	CbGpPWpGaD
Dexmethylphenidate—Rash—Capecitabine—esophageal cancer	0.00065	0.000799	CcSEcCtD
Dexmethylphenidate—Dermatitis—Capecitabine—esophageal cancer	0.00065	0.000798	CcSEcCtD
Dexmethylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000647	0.00347	CbGpPWpGaD
Dexmethylphenidate—Headache—Capecitabine—esophageal cancer	0.000646	0.000794	CcSEcCtD
Dexmethylphenidate—Feeling abnormal—Methotrexate—esophageal cancer	0.000633	0.000778	CcSEcCtD
Dexmethylphenidate—SLC6A3—Neuronal System—ALDH2—esophageal cancer	0.000633	0.00339	CbGpPWpGaD
Dexmethylphenidate—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000628	0.000772	CcSEcCtD
Dexmethylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000622	0.00334	CbGpPWpGaD
Dexmethylphenidate—SLC6A2—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000621	0.00333	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Biological oxidations—ADH1B—esophageal cancer	0.000619	0.00332	CbGpPWpGaD
Dexmethylphenidate—Nausea—Capecitabine—esophageal cancer	0.000613	0.000753	CcSEcCtD
Dexmethylphenidate—Urticaria—Methotrexate—esophageal cancer	0.00061	0.00075	CcSEcCtD
Dexmethylphenidate—SLC6A3—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000609	0.00327	CbGpPWpGaD
Dexmethylphenidate—Abdominal pain—Methotrexate—esophageal cancer	0.000607	0.000746	CcSEcCtD
Dexmethylphenidate—Body temperature increased—Methotrexate—esophageal cancer	0.000607	0.000746	CcSEcCtD
Dexmethylphenidate—SLC6A2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000596	0.0032	CbGpPWpGaD
Dexmethylphenidate—SLC6A2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000596	0.0032	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000585	0.00314	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000577	0.0031	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.000576	0.00309	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000568	0.00305	CbGpPWpGaD
Dexmethylphenidate—Hypersensitivity—Methotrexate—esophageal cancer	0.000566	0.000695	CcSEcCtD
Dexmethylphenidate—SLC6A4—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000551	0.00296	CbGpPWpGaD
Dexmethylphenidate—Asthenia—Methotrexate—esophageal cancer	0.000551	0.000677	CcSEcCtD
Dexmethylphenidate—SLC6A3—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00055	0.00295	CbGpPWpGaD
Dexmethylphenidate—Pruritus—Methotrexate—esophageal cancer	0.000543	0.000668	CcSEcCtD
Dexmethylphenidate—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.000535	0.00287	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.000528	0.00283	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000528	0.00283	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000528	0.00283	CbGpPWpGaD
Dexmethylphenidate—Diarrhoea—Methotrexate—esophageal cancer	0.000525	0.000646	CcSEcCtD
Dexmethylphenidate—Dizziness—Methotrexate—esophageal cancer	0.000508	0.000624	CcSEcCtD
Dexmethylphenidate—SLC6A4—Circadian rythm related genes—NOS2—esophageal cancer	0.000501	0.00269	CbGpPWpGaD
Dexmethylphenidate—Vomiting—Methotrexate—esophageal cancer	0.000488	0.0006	CcSEcCtD
Dexmethylphenidate—Rash—Methotrexate—esophageal cancer	0.000484	0.000595	CcSEcCtD
Dexmethylphenidate—Dermatitis—Methotrexate—esophageal cancer	0.000484	0.000594	CcSEcCtD
Dexmethylphenidate—Headache—Methotrexate—esophageal cancer	0.000481	0.000591	CcSEcCtD
Dexmethylphenidate—Nausea—Methotrexate—esophageal cancer	0.000456	0.00056	CcSEcCtD
Dexmethylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000452	0.00242	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.000436	0.00234	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.000415	0.00223	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.00041	0.0022	CbGpPWpGaD
Dexmethylphenidate—SLC6A2—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00041	0.0022	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.0004	0.00215	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.000389	0.00209	CbGpPWpGaD
Dexmethylphenidate—SLC6A4—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000376	0.00201	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000363	0.00195	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000331	0.00177	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000326	0.00175	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000311	0.00167	CbGpPWpGaD
Dexmethylphenidate—SLC6A4—Circadian rythm related genes—EP300—esophageal cancer	0.000307	0.00164	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000307	0.00164	CbGpPWpGaD
Dexmethylphenidate—SLC6A2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.00025	0.00134	CbGpPWpGaD
Dexmethylphenidate—SLC6A2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.00024	0.00129	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000221	0.00119	CbGpPWpGaD
Dexmethylphenidate—SLC6A4—Circadian rythm related genes—TP53—esophageal cancer	0.000219	0.00118	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000212	0.00114	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000167	0.000896	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000167	0.000896	CbGpPWpGaD
Dexmethylphenidate—SLC6A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.00016	0.000859	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—CA1—esophageal cancer	0.000142	0.000762	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000142	0.000762	CbGpPWpGaD
Dexmethylphenidate—SLC6A3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000142	0.000761	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—CA2—esophageal cancer	0.00013	0.000697	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000121	0.000648	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000121	0.000648	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000106	0.000568	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000101	0.000543	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—CYP26A1—esophageal cancer	9.85e-05	0.000528	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—ALOX15—esophageal cancer	9.59e-05	0.000515	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—TPI1—esophageal cancer	9.15e-05	0.000491	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—GSTO1—esophageal cancer	9.15e-05	0.000491	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—ALDOB—esophageal cancer	8.78e-05	0.000471	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—GAPDH—esophageal cancer	8.45e-05	0.000453	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—CRABP1—esophageal cancer	8.37e-05	0.000449	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—GNG7—esophageal cancer	7.96e-05	0.000427	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—ALDH2—esophageal cancer	7.46e-05	0.0004	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—GSTT1—esophageal cancer	7.1e-05	0.000381	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—CYP2A6—esophageal cancer	7.02e-05	0.000376	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—ENO1—esophageal cancer	6.65e-05	0.000357	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—PTGS1—esophageal cancer	6.65e-05	0.000357	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—PSME2—esophageal cancer	6.55e-05	0.000352	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—PSME1—esophageal cancer	6.55e-05	0.000352	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—CYP1B1—esophageal cancer	5.65e-05	0.000303	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—CYP19A1—esophageal cancer	5.32e-05	0.000285	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—HMOX1—esophageal cancer	4.85e-05	0.00026	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—ABCB1—esophageal cancer	4.66e-05	0.00025	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.11e-05	0.000167	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—NOS3—esophageal cancer	2.79e-05	0.000149	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—PTGS2—esophageal cancer	2.55e-05	0.000137	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—EP300—esophageal cancer	2.12e-05	0.000114	CbGpPWpGaD
Dexmethylphenidate—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.57e-05	8.41e-05	CbGpPWpGaD
